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ABSTRACT 
 
The prognosis of patients afflicted by glioblastoma remains poor. Biomarkers for the disease 
would be desirable in order to allow for an early detection of tumor progression or to indicate 
rapidly growing tumor subtypes requiring more intensive therapy. Here, we investigated 
whether a blood-derived specific miRNA fingerprint can be defined in patients with 
glioblastoma. To this end, miRNA profiles from the blood of 20 patients with glioblastoma 
and 20 age- and sex-matched healthy controls were compared. Of 1158 tested miRNAs, 52 
were significantly deregulated, as assessed by unadjusted Student´s t-test at an alpha level of 
0.05. Of these, 2 candidates, miR-128 (up-regulated) and miR-342-3p (down-regulated), 
remained significant after correcting for multiple testing by Benjamini Hochberg adjustment 
with a p-value of 0.025. The altered expression of these two biomarkers was confirmed in a 
second cohort of glioblastoma patients and healthy controls by real-time PCR and validated 
for patients who had received neither radio- nor chemotherapy and for patients who had their 
glioblastomas resected more than 6 months ago. Moreover, using machine learning, a 
comprehensive miRNA signature was obtained that allowed for the discrimination between 
blood samples of glioblastoma patients and healthy controls with an accuracy of 81% (95% 
confidence interval (CI) 78%-84%), specificity of 79% (95% CI 75%-83%) and sensitivity of 
83% (95% CI 71%-85%). In summary, our proof-of-concept study demonstrates that blood-
derived glioblastoma-associated characteristic miRNA fingerprints may be suitable 
biomarkers and warrant further exploration.  
 
 
Running title: Glioblastoma-associated miRNA profile in peripheral blood 
Key words: glioblastoma, microRNA, biomarker 
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INTRODUCTION 
 
Glioblastoma remains a major clinical challenge with median survival times around 5 months 
in population-based studies (Ohgaki and Kleihues 2005) and approximately 15 months within 
clinical trials (Stupp et al. 2005). The dismal prognosis is due to the infiltrative growth of the 
tumor and its resistance to conventional therapies leading to rapid tumor recurrence or 
progression. Monitoring of glioma growth during or after completed therapy always requires 
expensive procedures such as magnetic resonance imaging (MRI). In this regard, there is a 
major interest in developing biomarker strategies that allow for a less extensive monitoring of 
the disease in shorter time intervals. Further, patients at high risk for surgery-associated 
mortality or small tumors in eloquent areas of the brain could benefit from the discovery of 
biomarkers for the confirmation of glioblastoma in order to avoid biopsy. 
Biomarkers are helpful tools for the diagnosis and monitoring of patients suffering from 
different tumors. The clinically available molecules include - among others - prostate specific 
antigen for prostate cancer (Reed and Parekh 2010), carcinoembryonic antigen for 
gastrointestinal tumors (Denlinger and Cohen 2007), CA19-9 for pancreatic neoplasms 
(Boeck et al. 2006) and alpha fetoprotein for hepatocellular carcinoma (Chan et al. 2009). As 
a common feature, these proteins can easily be determined in the blood. However, no such 
protein biomarker is available for patients suffering from glioblastoma (Weller et al. 2010). 
Therefore, we assessed the suitability of blood-derived microRNAs (miRNAs) as potential 
diagnostic tools. miRNAs are short (17-24 nucleotides) non-coding RNAs which act as post-
transcriptional regulators of gene expression (Guarnieri and DiLeone 2008). They are 
involved in the regulation of physiological processes and differentially regulated under 
various pathological conditions (Calin and Croce 2006; Zhang et al. 2007). Deregulated 
miRNAs have been described in glioma cells and glioma tissue compared to normal brain and 
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several reports indicate that miRNAs contribute to the malignant phenotype of glioma cells 
(Malzkorn et al. 2010; Rao et al. 2010).   
More recently it became clear that disease-associated miRNAs are also detectable in blood, 
both in the cellular fraction and in serum (Chen et al. 2008). miRNAs may therefore represent 
useful and easy accessible molecules that can be exploited for diagnostic purposes (Chen et al. 
2008; Gilad et al. 2008). miRNA samples from blood can be analyzed by microarrays, real-
time PCR or next generation sequencing (NGS). Microarrays and PCR require only low 
amounts of RNA and are cost-effective compared to NGS. Further, PCR is in routine clinical 
use for different diagnostic approaches.  
Complex miRNA expression patterns, which usually contain more diagnostic information 
than single biomarkers, have already been used to define specific miRNA fingerprints in the 
blood associated with different tumor entities and non-neoplastic diseases (Keller et al. 2009b; 
Häusler et al. 2010; Hu et al. 2010). Accordingly, we explored blood-derived miRNA profiles 
from glioblastoma patients and healthy controls for their diagnostic potential using 
contemporary and comprehensive miRNA arrays. The results of this proof-of-principle study 
may help to establish novel approaches for tumor growth surveillance and prediction of 
responses to therapy in glioblastoma patients. 
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MATERIALS AND METHODS 
 
Samples 
The study was approved by the ethics committee of the canton of Zurich, Switzerland (E-
72/2009). All donors gave written informed consent before blood sampling. Twenty patients 
with a histopathological diagnosis of glioblastoma were included. The median age was 55 
years, ranging from 44-66 years. A detailed overview on the patients’ characteristics is given 
in Table 1. The control population consisted of 20 age- and sex-matched controls without 
acute or chronic diseases (median age: 58 years, age range 27-75 years). For validation, a set 
of 10 additional samples from glioblastoma patients (Table 2) and 10 healthy volunteers was 
collected. The median age was 59 for glioblastoma patients and 56 for healthy control donors. 
 
miRNA extraction and microarray screening 
PAXgene Blood RNA tubes (BD Biosciences, Basel, Switzerland) were used for blood 
sampling. Total RNA was extracted from the cellular fractions using the miRNeasy kit 
(Qiagen GmbH, Hombrechtikon, Switzerland). To this end, blood cells were pelleted by 
centrifugation and resuspended in 10 ml RNase-free water. Total RNA including the miRNA 
was isolated and then purified according to the manufacturer's protocol. RNA was eluted with 
40 µl RNase-free water. Subsequently, the RNA samples were frozen at -80°, shipped on dry 
ice and subjected to analysis by the Geniom “miRNA homo sapiens” Biochip on a Geniom 
real-time analyzer (GRTA, febit gmbh, Heidelberg, Germany). Each micro-fluidic device 
contained five replicates of 1158 known human mature miRNAs as annotated in the Sanger 
miRBase 14.0 (Griffiths-Jones et al. 2005; Griffiths-Jones et al. 2008). Before hybridization, 
no external labelling or amplification was carried out. All samples were processed fully 
automated on the GRTA following quality control.  For labelling, a microfluidic-based primer 
extension assay (MPEA) was carried out (Vorwerk et al. 2008). In more detail, 300 ng of total 
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RNA was mixed with 1 µl of 5 pM miRNA spike-in mix and dried in a table top speedvac 
(spike-in controls include: GCAAAGGCUAUCGUCAAGAGAUC; 
GUCGGCAUUUGGCUGGAACUUCAUA; UGACGGGUCUCUUCUUCGAUAGC; 
CAAAUCAACAAGAUGAGGUCUGGGG; CUUCCUGACCUUACCGAUUCCGA; 
UCAUUGCCUACAAGCCACCAAGC; GACAAAUCGGAUUCAAGGGCAGG; 
AGAUGUGGUUGCAACUUCGGAGC; UACCAACCCCACCAAAACCAAACGU; 
UCCAAAACCAAACCAAAUCCAAACC; ACAACCACUACUUCCGCCGUCAA; 
AACUCAAGCCGCCGGAAUCUUCA; AACACCCGUCAAGUCCAGUGCAU; 
UGCGCGGACUCCAACACUUUGUU, UGAUUGUUGUGACACCGGCACUACU). Each 
RNA pellet was fully resuspended in 25 µl of hybridization buffer and denatured for 3 
minutes at 95 °C. Until hybridization, the denatured samples were kept on ice. The success of 
the hybridization was monitored by cy3- and biotin-labeled hybridization controls including: 
[cy3]TCACTCATGGTTATGGCAGCACTGC,[bio]GTAGTTCGCCAGTTAATAGTTTGC
G,[bio]TCTTACCGCTGTTGAGATCCAGTTC,[bio]CCCACTCGTGCACCCAACTGATC
TT,[bio]CCATCCAGTCTATTAATTGTTGCG. After 16 h hybridization at 42°C, the 
biochip was washed automatically and a program for signal enhancement was processed with 
the GRTA. Results were analyzed using the Geniom Wizard Software (febit biomed gmbh, 
Heidelberg). Then, for each array and each miRNA (feature), the median signal intensity of 
all pixels belonging to the respective feature was extracted from the raw data file such that for 
each miRNA five intensity values were calculated corresponding to each replicate copy of 
miRBase on the array. 
Following background correction, median values were calculated from the five replicate 
intensity values of each miRNA in order to provide a stable estimate of the actual miRNA 
intensity value. To normalize arrays, Quantile Normalization was carried out using the freely 
available R software (http://www.R-project.org). All further analyses were carried out using 
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the normalized and background-subtracted intensity values. All microarray data were stored at 
the febit in-house database and can be accessed via the web-interface of the “Human Disease 
miRNome” project (http://genetrail.bioinf.uni-sb.de/wholemirnomeproject).  
 
Statistical analysis 
The approximate normal distribution of the measured data was verified by Shapiro-Wilk test 
followed by adjustment for multiple testing. Next, miRNAs showing a different behaviour in 
the two groups were identified by unpaired two-tailed parametric t-test. p-values obtained for 
each individual miRNA were adjusted for multiple testing by Benjamini-Hochberg 
(Benjamini et al. 2001) adjustment. Furthermore, the Area Under Curve (AUC) value of 
miRNAs was computed. AUC values are in the range from 0 to 1, where a value of 0.5 
indicates equal distribution among healthy and diseased subjects which corresponds to the 
least diagnostic information of a biomarker. An AUC value of 1 means that all expression 
intensities of the respective miRNA are higher in glioblastoma samples (up-regulated 
miRNA) while an AUC of 0 means that all expression values of the miRNA are higher in 
controls (down-regulated biomarker).  
In addition to the single biomarker analysis, samples were also classified according to miRNA 
patterns as calculated using Support Vector Machines (SVM) implemented in the R e1071 
package (Häusler et al. 2010). For each classification, we determined the specificity, 
sensitivity and accuracy. Here, the specificity corresponds to the percentage of correctly 
identified controls, i.e., true negatives divided by true negative plus false positives. A true 
negative (TN) denotes a control that is actually recognized as control and a false positive (FP) 
represents a control predicted to be a glioblastoma patient. Similarly, the sensitivity 
corresponds to the percentage of correctly identified glioblastoma samples, i.e., true positives 
divided by true positives plus false negatives. A true positive (TP) denotes a glioblastoma 
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patient that is actually recognized as patient and a false negative (FN) represents a patient 
predicted to be healthy. The accuracy represents the fraction of correct predictions, i.e. (TN + 
TP)/(TN + TP + FN + FP). Following classification, permutation tests were applied in order 
to check for putative overtraining. Here, the class labels were sampled at random and 
classifications were carried out using the permuted class labels. All statistical analyses were 
performed using version 2.11.1 of the R program (Keller et al. 2006). 
 
Real-time RT-PCR 
Real-time PCR was performed on the ABI PRISM 7000 Sequence Detection System using 
TaqMan microRNA assays for miR-128 and miR-342-3p (Applied Biosystems, Rotkreuz, 
Switzerland). RNU48 was assessed as endogenous control as previously described (Leidinger 
et al. 2010). The conditions for the PCR reactions were: 40 cycles, 95°C/15 s, 60°C/60 s. Data 
analysis was done using the CT method for relative quantification (Roth et al. 2010).  
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RESULTS 
 
We obtained 20 blood samples from patients with a histopathologically confirmed diagnosis 
of glioblastoma. An overview of the patient characteristics is provided in Table 1. Healthy 
volunteers with a matched distribution of age and sex served as controls.  
Altogether, 1158 mature miRNAs were quantitatively analyzed using a microarray platform. 
Following background subtraction and quantile normalization, all miRNAs with median 
intensity below 100 were considered lowly abundant and removed. The remaining 310 
miRNAs were then analyzed using computational approaches. To capture the similarity of the 
samples, we computed all pair-wise correlation coefficients. For controls, we found on 
average a correlation of 0.901 and a standard deviation of 0.046, for glioblastoma patients a 
slightly decreased averaged correlation of 0.887 at a standard deviation of 0.047, showing the 
high biological (inter-individual) reproducibility of the measured miRNA profiles. 
When comparing the filtered repertoire of the 310 miRNAs in glioblastoma patients and 
healthy controls, we observed a significant deregulation of 52 miRNAs, amounting to 16.8% 
of analyzed miRNAs. Of these, 27 miRNAs were up-regulated (52%) while 25 miRNAs were 
down-regulated (48%). The distribution of raw and respectively adjusted p-values across all 
miRNAs is presented as histogram plot in Figure 1. As shown there, after adjusting for 
multiple testing, a total of five miRNAs remained significant (p<0.05). Especially two 
miRNAs were significant with a p-value of 0.025, namely miR-128, the most up-regulated 
and miR-342-3p, the most down-regulated miRNA, in the blood of tumor patients. miR-128 
displayed a 1.7-fold increased median expression in samples from glioblastoma patients 
compared to healthy controls (intensity values of 665 vs. 397, p=0.0001 by unadjusted and 
0.025 by adjusted unpaired Student´s t-test; AUC = 0.828). The expression level of miR-342-
3p was decreased in the glioblastoma patients to 0.8 compared to the healthy donors (intensity 
values of 4738 vs. 5891, p=0.0002 by unadjusted and 0.025 by adjusted unpaired Student´s t-
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test; AUC = 0.18). The expression intensity of both miRNAs is shown in Fig. 2A together 
with the respective receiver operating characteristic (ROC) curves (Fig. 2B). The deregulation 
of miR-128 and miR-342-3p was confirmed in a second cohort of glioblastoma patients and 
control donors by real-time PCR (Table 3A). Additionally, we assessed the expression of both 
markers seperately by real-time PCR in the group of patients who had only undergone surgery 
at the time of blood sampling, as well as in the blood that had been obtained at least 6 months 
after surgery. Again, both miRNAs displayed a similar deregulation, independent of the time 
point of blood sampling or the recently received therapies (Table 3B). 
The complete list of 52 miRNAs that are significantly deregulated in glioblastoma samples 
compared to controls, without adjusting for multiple testing, in the microarray analysis is 
shown in Table 4 (in order of increasing p-values). Although single deregulated miRNAs will 
hardly be useful as suitable biomarkers, they may provide interesting information related to 
the disease. A comparison of our data with databases linking miRNAs to specific diseases 
demonstrated that 4 of these miRNA had previously been associated with gliomas according 
to the Human miRNA and Disease Database (HMDD) (Lu et al. 2008; Jiang et al. 2009). 
These include hsa-miR-146b which inhibits glioma cell migration and invasion by targeting 
MMPs (Xia et al. 2009) and was up-regulated here. Moreover, hsa-miR-19a and 15a which 
have been shown to be up-regulated in glioblastoma cell lines (Chaudhry et al. 2010), are also 
up-regulated in our blood-based study. Finally, miR-128 (which is missing in HMDD) has 
been described as down-regulated in glioblastoma tissue compared to normal human brain 
(Ciafre et al. 2005), but was up-regulated in blood of glioblastoma patients here. Besides these 
glioblastoma-linked candidates, we also detected a multitude of miRNAs that have not been 
put into the context of glioblastoma or other diseases. Therefore, our large-scale approach 
revealed a panel of potentially interesting candidate miRNAs that may be involved in the 
malignant phenotype of glioblastomas.  
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In the next step, we aimed at identifying tumor-specific miRNA fingerprints that allow for a 
classification of the samples as glioblastoma or healthy controls. To this end, we applied 
statistical learning techniques such as SVM with different kernels and a filter based subset 
selection, as mentioned in the methods section. Classification was performed as previously 
described (Keller et al. 2006; Keller et al. 2009a). We carried out 20 iterations of a 10-fold 
cross validation and 20 non-parametric permutations with class labels that were randomly 
assigned to either the tumor or the control group. To determine a suitable subset of miRNA 
biomarkers, we started the training process with the 2 most significantly regulated markers 
and iteratively increased the number of miRNAs contributing to the classification (in order of 
increasing p-values). The performance of the classification for increasing subset sizes in terms 
of accuracy, specificity and sensitivity is provided in Figure 3. As detailed in this figure, a 
radial basis function SVM achieved the best result with a subset of 180 miRNAs. The 
classification of the blood samples as “glioblastoma” respective “control group” was done 
with an accuracy of 81% (95% CI 78%-84%), specificity of 79% (95% CI 75%-83%), and 
sensitivity of 83% (95% CI 71%-85%). This means that on average 3 glioblastoma patients 
were predicted to be controls (false negatives, FN), while 17 glioblastoma patients were 
correctly predicted as patients (true positives, TP). Likewise, on average 4 controls were 
predicted to be glioblastoma patients (false positives, FP), while 16 controls were correctly 
identified (true negatives, TN). Thus, in our study with just n = 20 glioblastoma and n = 20 
control samples, the positive likelihood ratio, i.e., sensitivity divided by (1-specificity) 
computes as 3.95 while the negative likelihood ratio defined as (1-sensitivity) divided by 
specificity computes as 0.22.   
One classification example for this statistical model is presented in Figure 4. Here, ‘C’s 
denote healthy donors while ‘D’ denote glioblastoma patients, the value on the y-axis 
corresponds to the logarithm of quotient of the probability being diseased and the probability 
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being healthy. All samples above the separating horizontal line are classified more likely to be 
patients, respectively all samples below the horizontal line to be controls.  
In summary, the results of our analysis demonstrate a characteristic miRNA signature that can 
be obtained from the peripheral blood of glioblastoma patients.  
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DISCUSSION 
 
Despite recent advances in the treatment of patients afflicted by glioblastoma, the prognosis 
remains poor (Stupp et al. 2009). Since glioblastoma is not a common disease, screening of 
asymptomatic individuals or patients with unspecific neurological symptoms and signs is not 
warranted. However, during the course of the disease, rapid tumor progression or recurrence 
are frequently observed. In addition to imaging studies that are normally only available every 
2-3 months (Khayal et al. 2010), biomarkers might be helpful monitoring tools to detect 
tumor recurrence at the earliest time point or to distinguish between pseudoprogression and 
substantial tumor growth (Brandsma et al. 2008). The search for a blood-borne marker for 
glioblastoma has mostly focused on proteins (Hormigo et al. 2006; Gartner et al. 2010; Weller 
et al. 2010). However, glial fibrillary acidic protein (GFAP) which has been suggested as 
potential blood marker for gliomas (Jung et al. 2007) is rather unspecific since elevated GFAP 
levels are also observed in the blood of patients suffering from various different cerebral 
lesions (Foerch et al. 2006; Nylen et al. 2007). Likewise, other single proteins are lacking the 
required specificity and may also be difficult to detect due to posttranslational modificiations. 
The determination of complex protein patterns in the blood, however, requires extensive 
technical procedures (Ludwig et al. 2008; Ludwig et al. 2009; Somasundaram et al. 2009). 
Consequently, the number of protein markers that are in clinical use is very limited and 
restricted to few diseases (Meany et al. 2009). In contrast, miRNAs have the advantage of 
being clearly defined markers that can easily be determined on the basis of microarrays or 
real-time PCR. The ease of multiplexing further opens the road for the analysis of specific 
miRNA patterns that comprise numerous miRNAs.  
The present study aimed at laying a scientific basis for this approach and demonstrates that 
glioblastoma-specific miRNA fingerprints can be obtained from peripheral blood (Fig. 3 and 
4). This approach is particularly promising since blood can easily be sampled and subjected to 
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analysis. The confirmation of the microarray data by real-time PCR (Table 3A) indicates that 
the miRNA analysis can simply be done by broadly available technologies that are already in 
clinical use.  
Interestingly, we observed elevated expression levels of miR-128 in the blood of glioblastoma 
patients compared to healthy controls (Fig. 2). In contrast to our findings in the blood, miR-
128 is down-regulated in glioblastoma tissue compared to normal human brain (Ciafre et al. 
2005; Godlewski et al. 2008; Zhang et al. 2009). However, published signatures in blood, e.g. 
from multiple sclerosis and melanoma patients (Keller et al. 2009b; Leidinger et al. 2010), 
often show a non-significant overlap or even an inverse correlation with the tissue miRNA 
expression data that is available from the Human MiRNA Disease Database (HMDD) (Lu et 
al. 2008). For other diseases, tissue and blood show the same direction of deregulation, e.g. in 
non-small cell lung cancer (Shen et al. 2011) or artheriosclerosis obliterans (Li et al. 2011). 
Notably, the latter two studies did not consider, as in our case, blood cells but serum or 
plasma. Considering that in silico analysis using TargetScan predicts that several factors 
which are essential for TGF- processing and signal transduction (furin, TGF-receptor I, 
Smad2, Smad5, Smurf) are targeted by miR-128, while miR-128 expression in lymphocytes 
may be induced by TGF- (data not shown), the functional impact of increased miR-128 
levels in the blood of glioblastoma patients warrants further investigations. miR-342-3p, the 
second most deregulated miRNA (Fig. 2), has not yet been investigated in glioma tissues. An 
analysis in breast cancer tissue has, however, revealed a set of genes involved in cellular 
proliferation as potential targets of miR-342-3p (Van der Auwera et al. 2010). As with miR-
128, the functional relevance of miR-342-3p down-regulation in blood cells requires further 
evaluation. Apart from these 2 miRNAs, we also noticed other putative differentially 
regulated miRNAs that have only partially been linked to pathological conditions. One reason 
for this might the inclusion of recently described and still unexplored miRNAs in our array.  
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Considering the different treatment regimens that had been applied before inclusion in this 
study (Table 1 and 2), therapy-related effects can not be fully excluded. Recent findings 
suggest that changes in the miRNA repertoire of tumor cells may occur during chemotherapy 
(Rui et al. 2009; Zhou et al. 2010). However, while studies with larger patient cohorts and 
longitudinal blood sampling will be needed to fully address potential treatment-related effects 
on miRNAs in the blood of glioblastoma patients, these previous reports did not find miR-128 
and miR-342-3p (the most significantly deregulated miRNA of our study) to be modulated by 
chemotherapy. Furthermore, miR-128 and miR-342-3p were deregulated in a similar way in 
blood that was obtained immediatly after surgery versus blood from patients who had been 
operated more than 6 months previously and had received radio- and chemotherapy (Table 
3B). This indicates that the detected differences are linked to the disease and not to a 
particular treatment. Suitably expanded studies might also allow to stratify miRNA patterns 
according to patient age and tumor size and thereby sharpen the respective profiles. However, 
even with the limitations imposed by this pilot study, we were able to reveal the presence of 
glioblastoma-associated miRNA fingerprints in the blood. The values computed for 
sensitivity, specificity and accuracy (Fig. 3) are comparable to those obtained by blood-
derived miRNAs of ovarian or lung cancer patient cohorts (Keller et al. 2009a; Häusler et al. 
2010). Further analyses demonstrated that miRNA fingerprints from the glioblastoma cohort 
can be distinguished from miRNA profiles described for lung and ovarian cancer blood 
samples (data not shown). Additionally, miRNA profiles from glioblastoma patients also 
differ from miRNA profiles of non-neoplastic diseases involving the nervous system such as 
multiple sclerosis (Keller et al. 2009b).  
Due to the lack of any biomarker that is in clinical use for glioblastoma, the findings of our 
case-control study may lay the scientific basis for further studies using miRNAs for the 
follow-up of patients diagnosed with glioblastoma. Although the findings of our initial 
microarray screening were validated by real-time PCR, we are aware that our study still 
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represents a hypothesis generating proof-of-concept study on a rather small cohort and that 
these findings have to be validated on extended cohorts in order to advance the use of 
miRNAs as multiplex diagnostic tests for glioblastoma. Combination of this novel strategy 
with clinical and image-guided monitoring may help to improve the surveillance of 
glioblastoma patients during the course of the disease or the stratification of patients based on 
blood-derived profiles. Beyond a diagnostic multiplex test for glioblastoma, our research also 
opens new avenues for other ongoing research. Finally, the knowledge on altered miRNA 
profiles in immune cells might enable an improved understanding of glioblastoma-induced 
immunosuppression, which could on a very long term perspective lead to improved 
immunotherapeutic approaches.  
In summary, blood-derived glioblastoma-associated miRNAs hold promise as biomarkers for 
the disease and warrant further exploration based on the findings of this pilot study. 
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Figure legends 
 
Fig. 1. Distribution of raw and adjusted p-values for the deregulation of individual 
miRNAs. 310 out of 1158 analysed miRNAs were abundant enough to allow for 
bioinformatic evaluation by Shapiro-Wilk test followed by an adjustment for multiple testing. 
Expression levels in the glioblastoma (n=20) and control (n=20) cohorts were compared by 
unpaired two-tailed parametric t-test and the number of individual p-values falling into the 
respective segments of width 0.05 were plotted as histogram (A). A similar histogram was 
generated from p-values obtained after Benjamini Hochberg adjustment for multiple 
comparisons (B). Vertical black lines denote the alpha level of 0.05. 
 
Fig. 2. miR-128 and miR-342-3p are deregulated in glioma samples. The expression of 
miR-128 and miR-342-3p in blood samples of glioblastoma patients and healthy control 
donors was assessed by microarrays. A. Back-to-back histograms for miR-128 and miR-342-
3p with glioblastoma samples (dark) and controls (pale). The y-axis shows the measured array 
intensity. B. ROC curves showing the true positive rate as function of the false positive rate 
are presented for miR-128 and miR-342-3p. 
 
Fig. 3. Relationship between discriminatory power of miRNA profiles and size of the 
selected subsets. Support vector machines with different kernels were used to perform 20 
iterations of a 10-fold cross validation, incorporating different numbers of miRNA. The plot 
shows the performance metrics of the classification using 22 miRNA subsets with increasing 
number of biomarkers. Accuracy (dark grey), specificity (light grey) and sensitivity (black) 
were evaluated. 
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Fig. 4. Classification of samples from glioblastoma patients or healthy controls. Based on 
the respective miRNA pattern, the quotient of the probability that the sample originates from a 
diseased patient divided by the probability that the donor is healthy is indicated for each 
sample. Samples with logarithms of above 0 (indicated by the dashed horizontal line) are 
more likely to be from diseased patients, i.e. to be glioblastoma samples. The vertical dashed 
line separates controls (‘C’) from glioblastoma samples (‘D’). False negatives are marked by 
dotted circles (lower right corner) while false positives are marked by solid circles (upper left 
corner). 
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Tables: 
Table 1: Patient characteristics 
Number age sex prior therapies 
1 62 m surgery 
2 61 f surgery 
3 51 m surgery, RT, TMZ 
4 66 m surgery, RT, TMZ 
5 44 m surgery 
6 53 f surgery, RT 
7 48 m surgery, RT, TMZ, BEV 
8 54 f surgery, RT, TMZ 
9 51 m surgery, RT 
10 61 f surgery, RT 
11 54 f surgery, RT, TMZ 
12 63 m surgery, RT, TMZ, BEV 
13 53 f surgery, RT, TMZ, BEV 
14 46 m surgery, RT, TMZ, gefitinib 
15 52 m surgery, RT, TMZ 
16 51 m surgery, RT, TMZ 
17 60 f surgery 
18 59 m surgery, RT, TMZ 
19 55 m surgery 
20 59 f surgery 
 
RT: radiotherapy, TMZ: temozolomide, BEV: bevacizumab
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Table 2: Patient characteristics 
Number age sex prior therapies 
1 35 f surgery, RT 
2 52 m surgery, RT, TMZ 
3 66 m surgery, RT, TMZ 
4 37 m surgery 
5 59 m surgery 
6 74 m surgery 
7 60 m surgery, RT 
8 54 f surgery, RT, TMZ 
9 60 f surgery, RT, TMZ 
10 71 m surgery 
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Table 3A: miRNA expression fold changes assessed by microarray and real-time RT-PCR 
miRNA fold change microarray 
fold change 
real-time PCR 
miR-128 1.68 1.50 
miR-342-3p 0.80 0.76 
 
 
Table 3B: miRNA expression fold changes assessed by real-time RT-PCR 
miRNA surgery only > 6 months after surgery 
miR-128 1.42 1.69 
miR-342-3p 0.58 0.79 
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Table 4: miRNAs showing differential expression between glioblastoma samples and healthy 
control.  
 
median 
glioblastoma 
median 
control 
fold 
change 
unadjusted 
p-value 
adjusted 
p-value AUC 
hsa-miR-128 664.9 396.7 1.68 0.0001 0.0252 0.828 
hsa-miR-342-3p 4738.1 5890.6 0.80 0.0002 0.0252 0.180 
hsa-miR-194 7562.5 5173.6 1.46 0.0006 0.0407 0.789 
hsa-life-6-3p 76.8 144.8 0.53 0.0006 0.0407 0.199 
hsa-miR-628-3p 159.1 285.8 0.56 0.0007 0.0407 0.186 
hsa-miR-148a 982.6 693.4 1.42 0.0017 0.0689 0.791 
hsa-miR-30d 6044.9 3978.5 1.52 0.0019 0.0689 0.779 
hsa-miR-574-3p 2508.0 5173.6 0.48 0.0020 0.0689 0.241 
hsa-miR-223 2011.3 1026.5 1.96 0.0020 0.0689 0.804 
hsa-miR-197 793.1 1178.3 0.67 0.0024 0.0734 0.225 
hsa-miR-130b 1780.2 2850.1 0.62 0.0030 0.0801 0.221 
hsa-miR-320b 3399.8 6206.3 0.55 0.0031 0.0801 0.240 
hsa-miR-3195 144.3 211.1 0.68 0.0037 0.0877 0.246 
hsa-miR-485-3p 81.9 130.0 0.63 0.0040 0.0879 0.233 
hsa-miR-19a 2363.7 1717.0 1.38 0.0050 0.1032 0.746 
hsa-miR-550* 637.8 365.8 1.74 0.0053 0.1032 0.748 
hsa-miR-320a 20745.7 33712.7 0.62 0.0057 0.1047 0.251 
hsa-miR-484 7407.5 4558.3 1.63 0.0061 0.1053 0.754 
hsa-miR-941 89.1 133.3 0.67 0.0070 0.1079 0.228 
hsa-miR-145 252.4 144.5 1.75 0.0072 0.1079 0.726 
hsa-miR-151-3p 1057.0 617.0 1.71 0.0073 0.1079 0.794 
hsa-miR-423-5p 6015.3 11139.6 0.54 0.0082 0.1134 0.251 
hsa-miR-3196 435.1 810.5 0.54 0.0084 0.1134 0.274 
hsa-miR-138-1* 81.8 135.7 0.60 0.0110 0.1395 0.215 
hsa-miR-215 690.0 417.8 1.65 0.0114 0.1395 0.745 
hsa-miR-548o 76.5 141.7 0.54 0.0117 0.1395 0.273 
hsa-miR-362-3p 316.1 157.1 2.01 0.0147 0.1688 0.729 
hsa-miR-3194 138.9 220.1 0.63 0.0155 0.1721 0.275 
hsa-miR-486-3p 200.2 180.1 1.11 0.0167 0.1771 0.670 
hsa-miR-15a 4378.5 3063.7 1.43 0.0171 0.1771 0.715 
hsa-miR-30c 2243.8 1502.2 1.49 0.0191 0.1906 0.693 
hsa-miR-4281 230.7 389.3 0.59 0.0204 0.1959 0.261 
hsa-miR-1273d 90.9 127.3 0.71 0.0210 0.1959 0.263 
hsa-miR-320c 1159.5 1690.9 0.69 0.0229 0.1959 0.293 
hsa-miR-29c 393.8 228.1 1.73 0.0233 0.1959 0.686 
hsa-miR-646 110.4 156.8 0.70 0.0234 0.1959 0.304 
hsa-miR-424 248.4 185.6 1.34 0.0239 0.1959 0.711 
hsa-miR-22 7252.6 6790.3 1.07 0.0240 0.1959 0.685 
hsa-miR-4304 134.5 103.4 1.30 0.0252 0.2004 0.708 
hsa-miR-30a 486.8 328.9 1.48 0.0287 0.2190 0.683 
hsa-miR-320e 1211.5 1784.3 0.68 0.0291 0.2190 0.299 
hsa-life-27 412.7 595.1 0.69 0.0297 0.2190 0.313 
hsa-miR-149* 433.1 740.5 0.58 0.0317 0.2218 0.328 
hsa-miR-331-3p 1222.4 939.1 1.30 0.0317 0.2218 0.671 
hsa-miR-185 20745.7 18984.1 1.09 0.0322 0.2218 0.640 
hsa-miR-1912 113.2 169.9 0.67 0.0343 0.2312 0.313 
hsa-miR-1228* 908.1 1292.2 0.70 0.0365 0.2408 0.339 
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hsa-miR-146b-5p 183.2 156.0 1.17 0.0377 0.2435 0.635 
hsa-miR-18a* 253.5 162.9 1.56 0.0405 0.2561 0.688 
hsa-miR-1915 432.6 599.0 0.72 0.0419 0.2596 0.296 
hsa-miR-100 164.4 334.3 0.49 0.0493 0.2951 0.358 
hsa-miR-143 198.8 101.0 1.97 0.0497 0.2951 0.733 
 
 
Annotation (Table 4): 
The columns present median values for glioblastoma and control samples and the fold change 
(glioblastoma vs. control) represents their ratio. P-values were calculated using Student’s t-
test. Adjusted p-values were determined according to the method by Benjamini and 
Hochberg. AUC denote the area under the ROC curve. Significant miRNAs are highlighted in 
bold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
